Blood test could transform liver transplant monitoring

NCT ID NCT04793360

Ongoing Knowledge-focused Sponsor: CareDx Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated Jun 21, 2026 · Updated 26 times

Summary

This study is testing a new blood test called LiverCare to see if it can better monitor liver transplant recipients for complications like rejection. Researchers will follow 1,500 patients for up to a year, comparing the new test with standard monitoring. The goal is to improve early detection and outcomes without extra needle sticks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Atrium Health

Charlotte, North Carolina, 28204, United States
Baylor College of Medicine

Houston, Texas, 77030, United States
Beth Israel Deaconess Medical Center (BIDMC)

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27710, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
INTEGRIS Baptist Medical Center

Oklahoma City, Oklahoma, 73112, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Intermountain Medical Center

Murray, Utah, 84107, United States
Keck Medical Center of USC

Los Angeles, California, 90033, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Medical Unversity of South Carolina

Charleston, South Carolina, 29425, United States
Methodist Health System

Dallas, Texas, 75203, United States
Piedmont Healthcare

Atlanta, Georgia, 30309, United States
Tampa General Hospital

Tampa, Florida, 33606, United States
Tulane University

New Orleans, Louisiana, 70112, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Maryland Medical Center

Baltimore, Maryland, 21201, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center/ Nebraska Medicine

Omaha, Nebraska, 68198, United States
University of Tennessee_Methodist Healthcare

Memphis, Tennessee, 38104, United States
University of Washington

Seattle, Washington, 98195, United States
Virginia Commonwealth University

Richmond, Virginia, 23219, United States
Washington Unversity in St. Louis

St Louis, Missouri, 63110, United States
Westchester Medical Center

Valhalla, New York, 10595, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LiverCare blood test kit (device for blood collection and analysis)

What this could lead to

If successful, this could lead to a more accurate and less invasive way to monitor liver transplant patients, potentially catching problems like rejection earlier.

What could go wrong

This is an observational study, not a treatment trial. The test may not prove better than current monitoring methods, and results may not apply to all patients.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOMARKERS LIVER TRANSPLANTATION LIVER TRANSPLANTATION